Entry
Name
Relaxin signaling pathway - Homo sapiens (human)
Description
Human relaxin-2 ("relaxin"), originally identified as a peptidic hormone of pregnancy, is now known to exert a range of pleiotropic effects including vasodilatory, anti-fibrotic and angiogenic effects in both males and females. It belongs to the so-called relaxin peptide family which includes the insulin-like peptides INSL3 and INSL5, and relaxin-3 (H3) as well as relaxin. INSL3 has clearly defined specialist roles in male and female reproduction, relaxin-3 is primarily a neuropeptide involved in stress and metabolic control, and INSL5 is widely distributed particularly in the gastrointestinal tract. These members of relaxin peptide family exert such effects binding to different kinds of receptors, classified as relaxin family peptide (RXFP) receptors: RXFP1, RXFP2, RXFP3, and RXFP4. These G protein-coupled receptors predominantly bind relaxin, INSL3, relaxin-3, and INSL-5, respectively. RXFP1 activates a wide spectrum of signaling pathways to generate second messengers that include cAMP and nitric oxide, whereas RXFP2 activates a subset of these pathways. Both RXFP3 and RXFP4 inhibit cAMP production, and RXFP3 activate MAP kinases.
Class
Organismal Systems; Endocrine system
BRITE hierarchy
Pathway map
Drug
D12181 Edasalonexent (USAN/INN)
Organism
Homo sapiens (human) [GN:
hsa ]
Gene
10488 CREB3; cAMP responsive element binding protein 3 [KO:K09048 ]
1277 COL1A1; collagen type I alpha 1 chain [KO:K06236 ]
1278 COL1A2; collagen type I alpha 2 chain [KO:K06236 ]
1281 COL3A1; collagen type III alpha 1 chain [KO:K19720 ]
1282 COL4A1; collagen type IV alpha 1 chain [KO:K06237 ]
1284 COL4A2; collagen type IV alpha 2 chain [KO:K06237 ]
1285 COL4A3; collagen type IV alpha 3 chain [KO:K06237 ]
1286 COL4A4; collagen type IV alpha 4 chain [KO:K06237 ]
1287 COL4A5; collagen type IV alpha 5 chain [KO:K06237 ]
1288 COL4A6; collagen type IV alpha 6 chain [KO:K06237 ]
1385 CREB1; cAMP responsive element binding protein 1 [KO:K05870 ]
1386 ATF2; activating transcription factor 2 [KO:K04450 ]
1388 ATF6B; activating transcription factor 6 beta [KO:K09049 ]
148327 CREB3L4; cAMP responsive element binding protein 3 like 4 [KO:K09048 ]
1910 EDNRB; endothelin receptor type B [KO:K04198 ]
2277 VEGFD; vascular endothelial growth factor D [KO:K05449 ]
2353 FOS; Fos proto-oncogene, AP-1 transcription factor subunit [KO:K04379 ]
2769 GNA15; G protein subunit alpha 15 [KO:K04637 ]
2770 GNAI1; G protein subunit alpha i1 [KO:K04630 ]
2771 GNAI2; G protein subunit alpha i2 [KO:K04630 ]
2773 GNAI3; G protein subunit alpha i3 [KO:K04630 ]
2775 GNAO1; G protein subunit alpha o1 [KO:K04534 ]
2790 GNG10; G protein subunit gamma 10 [KO:K04545 ]
2791 GNG11; G protein subunit gamma 11 [KO:K04546 ]
2792 GNGT1; G protein subunit gamma transducin 1 [KO:K04548 ]
2793 GNGT2; G protein subunit gamma transducin 2 [KO:K04549 ]
2885 GRB2; growth factor receptor bound protein 2 [KO:K04364 ]
3265 HRAS; HRas proto-oncogene, GTPase [KO:K02833 ]
339403 RXFP4; relaxin family peptide/INSL5 receptor 4 [KO:K08398 ]
3725 JUN; Jun proto-oncogene, AP-1 transcription factor subunit [KO:K04448 ]
3845 KRAS; KRAS proto-oncogene, GTPase [KO:K07827 ]
4322 MMP13; matrix metallopeptidase 13 [KO:K07994 ] [EC:3.4.24.-]
468 ATF4; activating transcription factor 4 [KO:K04374 ]
4790 NFKB1; nuclear factor kappa B subunit 1 [KO:K02580 ]
4893 NRAS; NRAS proto-oncogene, GTPase [KO:K07828 ]
51289 RXFP3; relaxin family peptide receptor 3 [KO:K08397 ]
5290 PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922 ] [EC:2.7.1.153 ]
5291 PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922 ] [EC:2.7.1.153 ]
5293 PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922 ] [EC:2.7.1.153 ]
5295 PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649 ]
5296 PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649 ]
59 ACTA2; actin alpha 2, smooth muscle [KO:K12313 ]
59350 RXFP1; relaxin family peptide receptor 1 [KO:K04306 ]
5970 RELA; RELA proto-oncogene, NF-kB subunit [KO:K04735 ]
64764 CREB3L2; cAMP responsive element binding protein 3 like 2 [KO:K09048 ]
6654 SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099 ]
6655 SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099 ]
7040 TGFB1; transforming growth factor beta 1 [KO:K13375 ]
7422 VEGFA; vascular endothelial growth factor A [KO:K05448 ]
7423 VEGFB; vascular endothelial growth factor B [KO:K16858 ]
7424 VEGFC; vascular endothelial growth factor C [KO:K05449 ]
84699 CREB3L3; cAMP responsive element binding protein 3 like 3 [KO:K09048 ]
8503 PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649 ]
90993 CREB3L1; cAMP responsive element binding protein 3 like 1 [KO:K09048 ]
9586 CREB5; cAMP responsive element binding protein 5 [KO:K09047 ]
Compound
C01245 D-myo-Inositol 1,4,5-trisphosphate
C05981 Phosphatidylinositol-3,4,5-trisphosphate
Reference
Authors
Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan M, Summers RJ
Title
Relaxin family peptides and their receptors.
Journal
Reference
Authors
Cernaro V, Lacquaniti A, Lupica R, Buemi A, Trimboli D, Giorgianni G, Bolignano D, Buemi M
Title
Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein.
Journal
Reference
Authors
van der Westhuizen ET, Halls ML, Samuel CS, Bathgate RA, Unemori EN, Sutton SW, Summers RJ
Title
Relaxin family peptide receptors--from orphans to therapeutic targets.
Journal
Reference
Authors
Halls ML, van der Westhuizen ET, Bathgate RA, Summers RJ
Title
Relaxin family peptide receptors--former orphans reunite with their parent ligands to activate multiple signalling pathways.
Journal
Reference
Authors
Bathgate RA, Ivell R, Sanborn BM, Sherwood OD, Summers RJ
Title
International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides.
Journal
Reference
Authors
Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ
Title
Cardiovascular effects of relaxin: from basic science to clinical therapy.
Journal
Reference
Authors
Nistri S, Bani D
Title
Relaxin receptors and nitric oxide synthases: search for the missing link.
Journal
Reference
Authors
Samuel CS, Hewitson TD, Unemori EN, Tang ML
Title
Drugs of the future: the hormone relaxin.
Journal
Reference
Authors
Sasser JM
Title
The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.
Journal
Reference
Authors
Sarwar M, Du XJ, Dschietzig TB, Summers RJ
Title
The actions of relaxin on the human cardiovascular system.
Journal
Reference
Authors
Bathgate RA, Ivell R, Sanborn BM, Sherwood OD, Summers RJ
Title
Receptors for relaxin family peptides.
Journal
Reference
Authors
Chow BS, Chew EG, Zhao C, Bathgate RA, Hewitson TD, Samuel CS
Title
Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.
Journal
Reference
Authors
Samuel CS, Du XJ, Bathgate RA, Summers RJ
Title
'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease.
Journal
Reference
Authors
Wilson SS, Ayaz SI, Levy PD
Title
Relaxin: a novel agent for the treatment of acute heart failure.
Journal
Reference
Authors
Halls ML, Bathgate RA, Summers RJ
Title
Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms.
Journal
Reference
Authors
Kocan M, Ang SY, Summers RJ
Title
Orthosteric, Allosteric and Biased Signalling at the Relaxin-3 Receptor RXFP3.
Journal
Reference
Authors
van der Westhuizen ET, Werry TD, Sexton PM, Summers RJ
Title
The relaxin family peptide receptor 3 activates extracellular signal-regulated kinase 1/2 through a protein kinase C-dependent mechanism.
Journal
Related pathway
hsa04270 Vascular smooth muscle contraction
KO pathway